These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 34709727)

  • 1. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
    Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
    Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping the SARS-CoV-2-Host Protein-Protein Interactome by Affinity Purification Mass Spectrometry and Proximity-Dependent Biotin Labeling: A Rational and Straightforward Route to Discover Host-Directed Anti-SARS-CoV-2 Therapeutics.
    Terracciano R; Preianò M; Fregola A; Pelaia C; Montalcini T; Savino R
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33430309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Open Science Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2.
    Bittremieux W; Adams C; Laukens K; Dorrestein PC; Bandeira N
    J Proteome Res; 2021 Mar; 20(3):1464-1475. PubMed ID: 33605735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular host factors for SARS-CoV-2 infection.
    Baggen J; Vanstreels E; Jansen S; Daelemans D
    Nat Microbiol; 2021 Oct; 6(10):1219-1232. PubMed ID: 34471255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The global succinylation of SARS-CoV-2-infected host cells reveals drug targets.
    Liu Q; Wang H; Zhang H; Sui L; Li L; Xu W; Du S; Hao P; Jiang Y; Chen J; Qu X; Tian M; Zhao Y; Guo X; Wang X; Song W; Song G; Wei Z; Hou Z; Wang G; Sun M; Li X; Lu H; Zhuang X; Jin N; Zhao Y; Li C; Liao M
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2123065119. PubMed ID: 35858407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.
    Wang M; Withers JB; Ricchiuto P; Voitalov I; McAnally M; Sanchez HN; Saleh A; Akmaev VR; Ghiassian SD
    Life Sci Alliance; 2021 May; 4(5):. PubMed ID: 33593923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
    More SA; Patil AS; Sakle NS; Mokale SN
    Virology; 2021 Mar; 555():10-18. PubMed ID: 33421743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
    Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
    Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
    van de Leemput J; Han Z
    Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
    Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
    J Genet; 2021; 100(1):. PubMed ID: 33707363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
    Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
    Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV.
    Stukalov A; Girault V; Grass V; Karayel O; Bergant V; Urban C; Haas DA; Huang Y; Oubraham L; Wang A; Hamad MS; Piras A; Hansen FM; Tanzer MC; Paron I; Zinzula L; Engleitner T; Reinecke M; Lavacca TM; Ehmann R; Wölfel R; Jores J; Kuster B; Protzer U; Rad R; Ziebuhr J; Thiel V; Scaturro P; Mann M; Pichlmair A
    Nature; 2021 Jun; 594(7862):246-252. PubMed ID: 33845483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-scale metabolic modeling reveals SARS-CoV-2-induced metabolic changes and antiviral targets.
    Cheng K; Martin-Sancho L; Pal LR; Pu Y; Riva L; Yin X; Sinha S; Nair NU; Chanda SK; Ruppin E
    Mol Syst Biol; 2021 Nov; 17(11):e10260. PubMed ID: 34709707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective inhibition of coronavirus replication by
    Xu H; Li J; Song S; Xiao Z; Chen X; Huang B; Sun M; Su G; Zhou D; Wang G; Hao R; Wang N
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):789-798. PubMed ID: 34719206
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
    Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
    Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses.
    Tampere M; Pettke A; Salata C; Wallner O; Koolmeister T; Cazares-Körner A; Visnes T; Hesselman MC; Kunold E; Wiita E; Kalderén C; Lightowler M; Jemth AS; Lehtiö J; Rosenquist Å; Warpman-Berglund U; Helleday T; Mirazimi A; Jafari R; Puumalainen MR
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33322045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
    Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets.
    Bojkova D; Klann K; Koch B; Widera M; Krause D; Ciesek S; Cinatl J; Münch C
    Nature; 2020 Jul; 583(7816):469-472. PubMed ID: 32408336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins.
    May DG; Martin-Sancho L; Anschau V; Liu S; Chrisopulos RJ; Scott KL; Halfmann CT; Díaz Peña R; Pratt D; Campos AR; Roux KJ
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.